Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours

British Journal of Cancer

Volumn 89, Issue 10, 2003, Pages 1889-1895

  Checkley, D ^a   Tessier, J J ^a   Kendrew, J ^a   Waterton, J C ^a   Wedge, S R ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

DCE MRI; Gadopentetate dimeglumine; Tyrosine kinase inhibitor; Vascular permeability; VEGF; ZD6474

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE; PROTEIN TYROSINE KINASE INHIBITOR; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EVALUATION; HUMAN; HUMAN TISSUE; LONG TERM CARE; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; CAPILLARY PERMEABILITY; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICE; NEOPLASMS, EXPERIMENTAL; PIPERIDINES; PROSTATIC NEOPLASMS; QUINAZOLINES; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0346752528     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601386     Document Type: Article

References (36)

1. Bates DO, Hillman NJ, Williams B, Neal CR, Pocock TM (2002) Regulation of microvascular permeability by vascular endothelial growth factors. J Anat 200: 581-597
2. Bhujwalla ZM, Artemov D, Natarajan K, Ackerstaff E, Solaiyappan M (2001) Vascular differences detected by MRI for metastatic vs nonmetastatic breast and prostate cancer xenografts. Neoplasia 3: 143-153
3. Brasch RC, Li KC, Husband JE, Keogan MT, Neeman M, Padhani AR, Shames D, Turetschek K (2000) In vivo monitoring of tumor angiogenesis with MR imaging. Acad Radiol 7: 812-823
4. Brekken RA, Overholser JP, Stasny VA, Waltenberger J, Minna JD, Thorpe PE (2000) Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 60: 5117-5124
5. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholtz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-583
6. Checkley D, Tessier JJ, Wedge SR, Dukes M, Kendrew J, Curry B, Middleton B, Waterton JC (2003) Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts. Mag Res Imaging 21: 475-482
7. Dafni H, Landsman L, Schechter B, Kohen F, Neeman M (2002) MRI and fluorescence microscopy of the acute vascular response to VEGF165: vasodilation, hyper-permeability and lymphatic uptake, followed by rapid inactivation of the growth factor. NMR Biomed 15: 120-131
8. Dibbens JA, Miller DL, Damert A, Risau W, Vadas MA, Goodall GJ (1999) Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements. Mol Biol Cell 10: 907-919
9. Drevs J, Esser N, Konerding MA, Wolloscheck T, Wedge SR, Ryan AJ, Ogilvie DJ, Unger C, Marme D (2002a) Effect of ZD6474, a VEGF receptor tyrosine kinase inhibitor, on primary tumor growth, metastasis, vessel density and microvascular architecture in murine renal cell carcinoma. Proc Am Assoc Cancer Res 43, (Abst. 5358).
10. Drevs J, Müller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt H, Konerding MA, Allegrini PR, Wood J, Hennig J, Unger C, Marmé D (2002b) PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62: 4015-4022
11. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N (2001) Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 276: 3222-3230
12. Gossmann A, Helbich TH, Kuriyama N, Ostrowitzki S, Roberts TPL, Shames DM, van Bruggen N, Wendland MF, Israel MA, Brasch RC (2002) Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Mag Res Imaging 15: 233-240
13. Gossmann A, Helbich TH, Mesiano S, Shames DM, Wendland MF, Roberts TP, Ferrara N, Jaffe RB, Brasch RC (2000) Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor. Am J Obstet Gynecol 183: 956-963
14. Hennequin LF, Stokes ESE, Thomas AP, Johnstone C, Plé PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO (2002) Novel 4-anilinoquinazolines with C-7 basic side chains. Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 45: 1300-1312
15. Hillman NJ, Whittles CE, Pocock TM, Williams B, Bates DO (2001) Differential effects of vascular endothelial growth factor-C and placental growth factor-1 on the hydraulic conductivity of frog mesenteric capillaries. J Vasc Res 38: 176-186
16. Hurwitz HI, Holden SN, Eckhardt SG, Rosenthal M, de Boer R, Rischin D, Green M, Basser R (2002) Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. Proc Amer Soc Clin Oncol 21, (Abst. 325.)
17. Igarashi H, Esumi M, Ishida H, Okada K (2002) Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer 95(1): 47-53
18. Jackson A, Jayson GC, Li KL, Zhu XP, Checkley DR, Tessier JJ, Waterton JC (2003) Reproducibility of quantitative dynamic contrast-enhanced MRI in newly-presenting glioma. Br J Radiol 76: 153-162
19. Joukov V, Kumar V, Sorsa T, Arighi E, Weich H, Saksela O, Alitalo K (1998) A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem 273: 6599-6602
20. Knopp MV, Weiss E, Sinn HP, Mattern J, Junkermann H, Radeleff J, Magener A, Brix G, Delorme S, Zuna I, van Kaick G (1999) Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 10: 260-266
21. Libutti SK, Choyke P, Carrasquillo JA, Bacharach S, Neumann RD (1999) Monitoring responses to antiangiogenic agents using noninvasive imaging tests. Cancer J Sci Am 5: 252-256
22. Luttun A, Brusselmans K, Fukao H, Tjwa M, Ueshima S, Herbert JM, Matsuo O, Collen D, Carmeliet P, Moons L (2002) Loss of placental growth factor protects mice against vascular permeability in pathological conditions. Biochem Biophys Res Commun 295: 428-434
23. Marzola P, Farace P, Calderan L, crescimanno C, Lunati E, Nicolato E, Benati D, Degrassi A, Terron A, Klapwijk J, Pesenti E, Sbarbati A, Osculati F (2003) In vivo mapping of fractional plasma volume (FPV) and endothelial transfer coefficient (KPS) in solid tumors using a macromolecular contrast agent: correlation with histology and ultrastructure. Int J Cancer 104: 462-468
24. Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Buttner M, Rziha H J, Dehio C (1999) A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 18: 363-374
25. Miles KA (2002) Functional computed tomography in oncology. Eur J Cancer 38: 2079-2084
26. Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M (1998) A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 273: 31273-31282
27. Pham CD, Roberts TP, van Bruggen N, Melnyk O, Mann J, Ferrara N, Cohen RL, Brasch RC (1998) Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 16: 225-230
28. Rak J, Mitsuhashi L, Bayo L, Filmus J, Shirasawa S, Sasazuki T, Kerbel R.S (1995) Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumour angiogenesis. Cancer Res 55: 4575-4580
29. Senger DR, Connolly DT, Van De Water L, Feder J, Dvorak HF (1990) Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50: 1774-1778
30. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10: 223-232
31. Tofts PS, Kermode AG (1991) Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17: 357-367
32. Waterton JC, Allott CP, Pickford R, Hamilton EA, Valcaccia B (1997) Assessment of mouse tumour xenograft volumes in vivo by ultrasound imaging, MRI and caliper measurement, Proceedings of 19th LH Gray Conference: Quantitative in Oncology 146-149
33. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ESE, Curry B, Richmond GHP, Wadsworth PF, Bigley AL, Hennequin LF (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62: 4645-4655
34. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF (2000) ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 60: 970-975
35. Wu HM, Yuan Y, Zawieja DC, Tinsley J, Granger HJ (1999) Role of phospholipase C, protein kinase C, and calcium in VEGF-induced venular hyperpermeability. Am J Physiol 276: H535-542
36. Zeng H, Sanyal S, Mukhopadhyay D (2001) Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. J Biol Chem 276: 32714-32719